<DOC>
	<DOCNO>NCT00552565</DOCNO>
	<brief_summary>The purpose study determine efficacy safety Rezular ( arverapamil ) treatment IBS-D .</brief_summary>
	<brief_title>Efficacy Study Rezular ( Arverapamil ) Treatment Irritable Bowel Syndrome With Diarrhea ( IBS-D )</brief_title>
	<detailed_description>We fulfil enrollment requirement study . This study design multicenter , randomize , double-blind , placebo control parallel dose group trial . The study open woman men . At screen patient assess see meet Rome III criterion IBS-D. After screen , patient undergo 14-day run-in period evaluation , eligibility randomize drug placebo determine . Patients complete daily telephone diary run-in double-blind phase study . Patients evaluate regularly schedule clinic visit double-blind phase study . Patients complete study may opportunity rollover open-label one-year safety study ( ARDIS-3 ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>fulfil Rome III criterion IBSD major cardiovascular disease psychiatric illness except mild moderate depression pregnancy presence GI disease could explain IBSlike symptom history major gastric , hepatic , pancreatic intestinal surgery perforation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>IBS , IBS-D , R-verapamil , Arverpamil , Rezular</keyword>
</DOC>